Premium
Reply to Costs of ALK , ROS1 , EGFR , and KRAS testing in non–small cell lung cancer: About different strategies in France
Author(s) -
Troncone Giancarlo
Publication year - 2017
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.29
H-Index - 57
eISSN - 1934-6638
pISSN - 1934-662X
DOI - 10.1002/cncy.21918
Subject(s) - kras , reimbursement , ros1 , medicine , lung cancer , multiplex , genotyping , oncology , turnaround time , cancer , health care , bioinformatics , adenocarcinoma , computer science , colorectal cancer , gene , genotype , biology , genetics , economics , economic growth , operating system